WEIGHT GAIN WITH OLANZAPINE, QUETIAPINE AND RISPERIDONE IN SUBJECTS WITH PSYCHOS

精神病患者服用奥氮平、喹硫平和利培酮后体重增加

• 批准号: 7377423
• 负责人: KAREN A GRAHAM
• 金额: $ 0.72万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377423
• 关键词: WEIGHT; GAIN; OLANZAPINE; QUETIAPINE; RISPERIDONE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research is to determine the cause of weight gain associated with taking the antipsychotic medications olanzapine (Zyprexa), quetiapine (Seroquel), and risperidone (Risperdal). As well, we hope to learn if we can predict which people are at risk for having weight gain when taking any of these medicines. We also want to know if these medicines affect blood sugar and lipid levels, which are risk factors for developing heart disease, and if they affect some of the hormones in our bodies that influence weight.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的目的是确定与服用抗精神病药物奥氮平（Zyprexa）、奎替鲁（Seroquel）和利培酮（Risperdal）相关的体重增加的原因。同时，我们希望了解我们是否可以预测哪些人在服用这些药物时有体重增加的风险。我们还想知道这些药物是否会影响血糖和血脂水平，这是患心脏病的危险因素，以及它们是否会影响我们体内影响体重的一些激素。